Stable outpatients with schizophrenia on antipsychotic treatment filled out short versions of the Drug Attitude Inventory (DAI) and Subjective Well-being on Neuroleoptics (SWN) questionnaires and their psychopathology was evaluated by PANSS. Subjective Well being was higher in patients who were in standard symptomatic remission compared to those non-remitted out patients.
Also patients on antipsychotic monothrerapy and with doses under the median dose of antipsychiotic in clp. equivavents had significantly more subjective satisfaction with the treatment. Subjective well being is an important index of the treatment outcome in patients on antipsychotics.